The FDA needs patient data to approve drugs. The patients with the rarest diseases have the least data. And that contradiction is exactly why synthetic data has crossed into regulatory relevance.
There are roughly 7,000 known rare diseases. Fewer than 5 percent have an approved treatment. The bottleneck is not biology but arithmetic. A Phase 3 trial for a common condition recruits thousands of patients in months. For a rare disease, the entire global patient population may be a few hundred. Recruiting a statistically powered control arm from that pool is often impossible, and sometimes unethical when a placebo would deny a sick patient access to an experimental therapy.
Generative AI has pried open this constraint. Models trained on limited real-world data (electronic health records, insurance claims, registries) can now produce synthetic patient cohorts that preserve the statistical properties of the original population without exposing any individual's protected health information. The approach is not theoretical. Replica Analytics, acquired by Aetion in 2022 and now operating as Aetion Generate, has deployed its synthesis engine with Fortune 50 life-science organizations that use synthetic versions of health data for rare-disease research while staying compliant with HIPAA and GDPR. A scoping review of 118 studies published in late 2025 found that synthetic data generation has become a mainstream tactic in rare-disease research, especially for medical imaging and clinical-trial simulation.
In March 2026 the FDA held an executive briefing on synthetic data and in-silico evidence. The agency is now shaping a framework for when AI-generated patient data can substitute for traditional placebo arms. The April 2025 decision to phase out mandatory animal testing for specific programs was a precursor. The logic is consistent: if a synthetic cohort can predict outcomes as accurately as a real one, requiring a human control arm adds cost and delays without adding safety.
The constraints are real. Synthetic data inherits every bias its training data contained. If the real-world data underrepresents a demographic group, the synthetic version will too. Validation standards are still fragmentary. Statistical similarity is not the same as biological plausibility, and a model that produces realistic-looking numbers can still generate clinically misleading signals. Researchers at Duke-Margolis have proposed a tiered framework linking the acceptable use of synthetic data to the regulatory consequence of the decision it supports.
The economics matter as much as the science. Rare-disease drug development already commands premium valuations: orphan drugs approved in 2025 carried a median per-patient cost above $200,000 annually, and the global orphan drug market is projected to reach $330 billion by 2028. But development costs have not fallen correspondingly. A single Phase 3 trial for a rare disease can run $50–100 million, with patient recruitment accounting for 30–40 percent of that spend. Synthetic control arms cut the recruitment variable. Cytel, a clinical trial analytics firm, now explicitly markets synthetic-data solutions for rare-disease programs, arguing that generative AI can compress the timeline from protocol to enrollment by eliminating the need to find and randomize a placebo group. For a small biotech with one shot at registration, removing that cost and delay can determine whether the program gets funded at all.
This technology will not replace clinical trials. But it may make rare-disease trials feasible where they are not today. For a biotech company deciding whether to invest 12 years and hundreds of millions into an orphan-drug program where patient recruitment alone can kill the economics, synthetic data shifts the question from "can we find enough patients" to "can we model them." That is a different category of problem.
